Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling

Sodium-glucose transporter 2 inhibitors (SGLT2is) exert significant cardiovascular and heart failure benefits in type 2 diabetes mellitus (DM) patients and can help reduce cardiac arrhythmia incidence in clinical practice. However, its effect on regulating cardiomyocyte mitochondria remain unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Jhuo, Shih-Jie, Lin, Yi-Hsiung, Liu, I-Hsin, Lin, Tsung-Hsien, Wu, Bin-Nan, Lee, Kun-Tai, Lai, Wen-Ter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095421/
https://www.ncbi.nlm.nih.gov/pubmed/37047815
http://dx.doi.org/10.3390/ijms24076842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095421/
https://www.ncbi.nlm.nih.gov/pubmed/37047815
http://dx.doi.org/10.3390/ijms24076842

Ejemplares similares